{
 "name": "景凱",
 "slug": "tw-6549",
 "aliases": [
  "景凱生物科技股份有限公司",
  "TaiwanJ",
  "6549"
 ],
 "ticker": "6549",
 "industry": "生技醫療業",
 "website": "http://taiwanj.com",
 "summary": "景凱（6549）是興櫃的生技醫療類股公司，2011 年成立，2015 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "景凱生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "TaiwanJ",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2015-10-21",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2011-05-02",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "石英珠",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "袁鴻昌",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 801220000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "http://taiwanj.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：JKB-122（Lodonal）",
   "value": "新冠病毒感染後持續症狀（PASC）｜FDA核准第IIb/III期IND，並授快速通道資格｜美國",
   "unit": "",
   "as_of": "2026-05-27",
   "source": "https://www.taiwanj.com/articles/article_view_tw/1030",
   "note": "公告載IND核准2026-04-20、Fast Track 2026-05-20；由授權夥伴Attune Biotech（原Biostax）推進，不是已獲上市核准。"
  },
  {
   "claim": "管線：JKB-122",
   "value": "自體免疫性肝炎｜第II期已完成（2019-01-21歷史試驗）｜美國",
   "unit": "",
   "as_of": "2020-07-21",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT02556372",
   "note": "NCT02556372；ClinicalTrials.gov最後公開更新 2020-07-21；登錄狀態 COMPLETED。此為歷史試驗完成紀錄，不把無日期官網所稱正在進行二期當2026現況。"
  },
  {
   "claim": "管線：JKB-122",
   "value": "對既往干擾素療法無反應之慢性C型肝炎｜第II期已終止（2017-08-30歷史試驗）｜台灣",
   "unit": "",
   "as_of": "2020-07-21",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT02293941",
   "note": "NCT02293941；ClinicalTrials.gov最後公開更新 2020-07-21；登錄狀態 TERMINATED。此為歷史試驗終止紀錄，不宣稱目前仍在開發或成功。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6549.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}